Inactive Instrument

Theratechnologies Inc.

TH

CA88338H7040

Theratechnologies Inc - ISS and Glass Lewis recommend voting 'for' Future PAK arrangement

Published on 09/02/2025 at 05:17 pm IST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Theratechnologies Inc.

26/25/26	Theratechnologies Inc.(NasdaqCM:THTX) dropped from S&P Global BMI Index	CI
26/25/26	CB Biotechnology, LLC completed the acquisition of Theratechnologies Inc. (TSX:TH).	CI
26/25/26	Theratechnologies Shares to Be Delisted From Nasdaq After Future Pak Finalizes Acquisition	MT
25/25/25	Theratechnologies Inc.(NasdaqCM:THTX) dropped from NASDAQ Composite Index	CI
22/25/22	Theratechnologies Inc.(NasdaqCM:THTX) added to S&P Global BMI Index	CI
17/25/17	Theratechnologies Gets Final Court Approval for Acquisition by Future Pak	MT
17/25/17	Theratechnologies receives final court approval on to be acquired by Future Pak	RE
12/25/12	Theratechnologies Shareholders Approve Acquisition by Future Pak	MT
12/25/12	Theratechnologies Inc. - Shareholder/Analyst Call
05/25/05	Theratechnologies Inc. Announces Availability of EGRIFTA WR (tesamorelin) for Injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy	CI
05/25/05	Theratechnologies Launches New Tesamorelin Formulation in US After FDA Approval	MT
05/25/05	Theratechnologies Brief: Announcing Availability Of EGRIFTA WR (Tesamorelin) For Injection To Reduce Excess Abdominal Fat In Adults With HIV And Lipodystrophy	MT
02/25/02	Theratechnologies Inc - ISS and Glass Lewis recommend voting 'for' Future PAK arrangement	RE
18/25/18	Theratechnologies Urges Shareholders to Vote in Favor of Future Pak Acquisition	MT
09/25/09	Theratechnologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2025	CI

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

Employees

103

Sector

Pharmaceuticals

More about the company